Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00460239 · ClinicalTrials.gov registry record · Phase 2
Buprenorphine's Dose Response Curve
A Phase 2 study, sponsored by Johns Hopkins University.
- Completed
- Registry status
- Phase 2
- Development phase
- 12
- Enrollment target
NCT00460239: Completed Phase 2 study, sponsored by Johns Hopkins University.
NCT00460239 is a Phase 2 study that has completed, run by Johns Hopkins University. The registered enrollment target is 12 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00460239, a Phase 2 study, has completed, sponsored by Johns Hopkins University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 12 participants
- Enrollment target
Study Summary
This is a residential study that looks at the effects of buprenorphine in persons who abuse but are not dependent on opioids. Animal studies show that very high doses of buprenorphine produce less effects than mid-range doses. This suggests that buprenorphine can be a very safe medication. However, no studies in humans have tested higher doses in a similar way. The goal of this study is to show the effects of single doses of buprenorphine, across a range of doses, in persons who are not physically dependent on opioids (but do abuse opioids).
Interventions
- DRUG Placebo
- DRUG Buprenorphine
- DRUG Morphine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2007-01 |
| Est. Completion | 2009-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00460239
The ClinicalTrials.gov registry entry for NCT00460239 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Johns Hopkins University, which has 1,448 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT00460239 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00460239 about?
NCT00460239 is a clinical study titled "Buprenorphine's Dose Response Curve". This is a residential study that looks at the effects of buprenorphine in persons who abuse but are not dependent on opioids. Animal studies show that very high doses of buprenorphine produce less effects than mid-range doses. This suggests that buprenorphine can be a very safe medication. However, ...
What is the current status of trial NCT00460239?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 12 participants. The study started on 2007-01. Estimated completion is 2009-07.
What interventions are being tested in trial NCT00460239?
The interventions under investigation include: Placebo (DRUG), Buprenorphine (DRUG), Morphine (DRUG).
Who is sponsoring clinical trial NCT00460239?
This trial is sponsored by Johns Hopkins University, which has 1,448 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.